---
figid: PMC9676472__fonc-12-1030232-g002
pmcid: PMC9676472
image_filename: fonc-12-1030232-g002.jpg
figure_link: /pmc/articles/PMC9676472/figure/f2/
number: FigureÂ 2
figure_title: ''
caption: 'MAP2K1 K57N in the MAPK pathway drives resistance to anti-EGFR therapy in
  metastatic colorectal cancer. Keys: MoAb, monoclonal antibodies. Created with BioRender.com.'
article_title: 'Case Report: MAP2K1 K57N mutation is associated with primary resistance
  to anti-EGFR monoclonal antibodies in metastatic colorectal cancer.'
citation: Gianluca Mauri, et al. Front Oncol. 2022;12:1030232.
year: '2022'

doi: 10.3389/fonc.2022.1030232
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.

keywords:
- MAP2K1
- MEK
- panitumumab
- resistance mechanisms
- colorectal cancer

---
